Back to top
more

Teva Pharmaceutical Industries Ltd. (TEVA)

(Delayed Data from NYSE)

$10.00 USD

10.00
9,041,165

+0.08 (0.81%)

Updated Aug 4, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.60%
2Buy19.21%
3Hold10.85%
4Sell6.62%
5Strong Sell3.32%
S&P50011.33%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (178 out of 252)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for TEVA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Teva Pharmaceutical Industries Ltd. falls in the month of December.

All items in Millions except Per Share data.

12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Assets          
Cash & Equivalents 2,177 1,975 1,782 963 988
Receivables 4,581 5,676 5,822 7,128 7,523
Notes Receivable 0 0 0 0 0
Inventories 4,403 4,422 4,731 4,924 4,954
Other Current Assets 1,844 1,391 1,459 2,367 3,496
Total Current Assets 13,005 13,464 13,794 15,382 16,961
Net Property & Equipment 6,296 6,436 6,868 7,673 8,073
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 695 386 368 574 725
Intangibles 29,547 36,078 38,922 46,054 65,896
Deposits & Other Assets 538 591 731 932 1,235
Total Assets 50,640 57,470 60,683 70,615 92,890
Liabilities & Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Notes Payable 0 0 0 0 0
Accounts Payable 1,756 1,718 1,853 2,069 2,157
Current Portion Long-Term Debt 3,188 2,345 2,216 3,646 3,276
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 2,465 2,562 2,738 3,563 4,264
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 5,757 7,048 7,515 8,643 8,822
Total Current Liabilities 13,164 13,674 14,322 17,921 18,519
Mortgages 0 0 0 0 0
Deferred Taxes/Income 964 1,096 2,140 3,277 5,215
Convertible Debt 0 0 0 0 0
Long-Term Debt 22,731 24,562 26,700 28,829 32,524
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 2,240 2,640 1,727 1,843 1,639
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 39,579 42,407 44,889 51,870 57,897
Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Preferred Stock 0 0 0 3,631 3,620
Common Stock (Par) 57 56 56 54 54
Capital Surplus 27,443 27,312 27,210 23,479 23,409
Retained Earnings -10,946 -6,956 -5,958 -3,803 13,607
Other Equity -1,364 -1,221 -1,372 -467 -1,503
Treasury Stock 4,128 4,128 4,142 4,149 4,194
Total Shareholder's Equity 11,061 15,063 15,794 18,745 34,993
Total Liabilities & Shareholder's Equity 50,640 57,470 60,683 70,615 92,890
Total Common Equity 11,061 15,063 15,794 15,114 31,373
Shares Outstanding 1,092.10 1,092.10 1,016.80 1,016.80 1,014.90
Book Value Per Share 10.13 13.79 15.53 14.86 30.91

Fiscal Year End for Teva Pharmaceutical Industries Ltd. falls in the month of December.

All items in Millions except Per Share data.

6/30/2021 3/31/2021 12/31/2020 9/30/2020 6/30/2020
Assets          
Cash & Equivalents 2,436 1,743 2,177 1,827 2,402
Receivables 4,488 4,572 4,581 4,385 4,545
Notes Receivable 0 0 0 0 0
Inventories 4,362 4,406 4,403 4,516 4,361
Other Current Assets 1,535 1,681 1,844 1,431 1,473
Total Current Assets 12,822 12,401 13,005 12,160 12,781
Net Property & Equipment 6,127 6,112 6,296 6,152 6,122
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 645 691 695 509 483
Intangibles 28,541 28,747 29,547 29,536 34,556
Deposits & Other Assets 530 524 538 822 560
Total Assets 49,195 49,004 50,640 49,737 54,991
Liabilities & Shareholders Equity 6/30/2021 3/31/2021 12/31/2020 9/30/2020 6/30/2020
Notes Payable 0 0 0 0 0
Accounts Payable 1,551 1,692 1,756 1,716 1,606
Current Portion Long-Term Debt 3,530 2,697 3,188 2,106 1,649
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 2,318 2,377 2,465 2,336 2,299
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 5,291 5,323 5,757 5,944 6,196
Total Current Liabilities 12,691 12,089 13,164 12,103 11,751
Mortgages 0 0 0 0 0
Deferred Taxes/Income 932 991 964 874 975
Convertible Debt 0 0 0 0 0
Long-Term Debt 21,602 22,288 22,731 23,515 24,616
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 2,215 2,240 2,181 2,411
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 37,884 38,029 39,579 39,145 40,167
Shareholders Equity 6/30/2021 3/31/2021 12/31/2020 9/30/2020 6/30/2020
Preferred Stock 0 0 0 0 0
Common Stock (Par) 57 57 57 57 57
Capital Surplus 27,503 27,474 27,443 27,403 27,374
Retained Earnings -10,662 -10,869 -10,946 -11,096 -6,747
Other Equity -1,459 -1,559 -1,364 -1,644 -1,731
Treasury Stock 4,128 4,128 4,128 4,128 4,128
Total Shareholder's Equity 11,311 10,975 11,061 10,592 14,824
Total Liabilities & Shareholder's Equity 49,195 49,004 50,640 49,737 54,991
Total Common Equity 11,311 10,975 11,061 10,592 14,824
Shares Outstanding 1,092.10 1,092.10 1,092.10 1,092.10 1,092.10
Book Value Per Share 10.36 10.05 10.13 9.70 13.57